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ABSTRACT
There are seven approved treatments for adults with chronic hepatitis B virus infec-
tion in the United States and European countries: interferon-α, pegylated interferon-α, 
lamivudine, adefovir dipivoxil, entecavir, telbivudine, and tenofovir disoproxil fuma-
rate. At present, two new analogues, entecavir and tenofovir are recommended as the 
first line therapy by the guidelines of European Association for the Study of the Liver 
and American Association Study for the Liver Diseases. On the other hand, regarding 
interferon therapy, use of pegylated interferon-α is recommended as the first line ther-
apy instead of standard interferon-α by both guidelines. Therefore, the main scientific 
interests and unmet medical needs for treatment of chronic hepatitis B have been 
narrowed down to long-term efficacy and safety of the two said analogues—entecavir 
and tenofovir—and combination therapy of pegylated interferon-α with the two ana-
logues. To put it concretely, further studies are needed to assess (1) the long-term effi-
cacy and safety and resistance to entecavir and tenofovir; (2) the efficacy of different 
durations (24 weeks to 2 years) and lower doses of pegylated interferon-α; (3) the role 
of combination therapy with two analogues to reduce resistance; and (4) the efficacy 
and safety of the two analogues with decompensated cirrhosis. Herein, we review the 
recent available data and results.
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  Implication for health policy/practice/research/medical education:
Several therapeutic modalities exist for the treatment of chronic hepatitis B. Based on recent available data, this review endeavors to 
present the long-term efficacy and safety of these modalities especially for entecavir and tenofovir as well as pegylated interferon-α. 
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1. Introduction
There are seven approved treatments for adults 
with chronic hepatitis B (CHB) in the United States 
and European countries: interferon (IFN) α, pegylated 
(PEG) IFN-α, lamivudine (LAM), adefovir dipivoxil (ADV), 
entecavir (ETV), telbivudine (TBV), and tenofovir disoproxil 
fumarate (TDF). IFN-α and LAM have been approved for 
children with hepatitis B virus (HBV) infection. Two 
different treatment strategies are applicable in both 
HBeAg-positive and negative CHB patients: treatment 
with PEG IFN-α and long-term treatment with NUCs. 
There are several treatment options for patients, making 
rational choices for the first and second line treatment 
sometimes difficult. Although available randomized 
controlled trials show encouraging short-term results 
demonstrating a favorable effect of these agents on 
intermediate markers of the disease such as HBV DNA 
level, liver enzyme tests, and liver histology, limited 
rigorous evidence exists demonstrating the effect 
of these therapies on important long-term clinical 
outcomes, such as the development of hepatocellular 
carcinoma or a reduction in mortality rate. Questions 
therefore remain about which groups of patients benefit 
from therapy and at which point in the course of disease Hepat Mon. 2011;11(8):601-611
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this therapy should be initiated.
Herein, we pooled the available data focusing on long-
term efficacy and safety of two new analogues—entecavir 
and tenofovir—and combination therapy of PEG INF-α 
and the said two analogues. In the first section, we 
summarize recent findings based on the consensus 
of the guidelines of the European Association for the 
Study of the Liver (EASL) and the American Association 
Study for the Liver Diseases (AASLD) (1, 2). In section two, 
presentations at EASL and AASLD annual meetings in 
2010 are reported.
2. Section I: Published Results Based on the 
Consensus of EASL and AASLD Guidelines
2.1. Assessment of Outcomes
Although various monitoring practices have been 
recommended, no clear evidence exists for an optimal 
approach. One proposed that the management algorithm 
used during therapy involves measuring HBV DNA and
ALT levels every 12 weeks and HBeAg or anti-HBe levels 
every 24 weeks in patients who are HBeAg-positive. For 
patients who are HBeAg-positive and achieve a complete 
response (undetectable HBV DNA), seroconversion 
to anti-HBe may offer the opportunity to discontinue 
therapy after 6–12 months of “consolidation.” During 
this period, regular monitoring of HBV DNA and 
HBeAg status should be done because relapse remains 
a possibility. HBsAg should be checked at 6-month 
intervals after HBe seroconversion if HBV DNA is 
undetectable. Quantitative HBsAg assay is still a research 
tool. HBeAg-negative patients should be similarly 
monitored for efficacy and safety through 48 weeks of 
treatment. A virological response with HBV DNA < 2000 
IU/mL (approximately 10,000 copies/mL), i.e. 3.3 log10 IU/
mL, is generally associated with remission of the liver 
disease. Undetectable HBV DNA in real-time PCR is the 
ideal desired of treatment sustained response with a 
high probability of HBsAg loss in the longer term. HBsAg 
should be checked at 6-month intervals if HBV DNA is 
undetectable. All patients treated with PEG IFN-α should 
Treatment 
Group
HBeAg 
Status
HBV DNA 
Suppression 
(log10 copies/mL)
HBV DNA 
Undetectable, %
ALT Normalization % HBeAg Serocon- Version %
LAM a (3, 4) Positive
Negative
- 5.4
- 4.5
36
72
60
71
18
―
ADV a (5, 6) Positive
Negative 
- 3.5
- 3.9
21
51
48
72
12
―
ETV a (3, 4) Positive
Negative
-6.9
- 5.0
67
90
68
78
21
―
TBV a (7) Positive
Negative 
- 6.4
- 5.2
60
88
77
74
23
―
TDF a (8) Positive
Negative 
- 4.5 (12w)
- 3.0 (12w)
76
93
68
76
21
―
Table 1. Summary of NUCs Treatment in Patients with HBeAg-Positive and -Negative Chronic Hepatitis B: 48 Weeks Post-Treatment Results
a Abbreviations:  ADV, Adefovir; ETV, Entecavir; LAM, Lamivudine;  TDF, Tenofovir;  TVB, Telbivudine
be monitored for the known adverse effects of IFN. The 
balance of benefits and harms associated with screening 
for hepatocellular carcinoma is unknown and is an area 
for future research.
2.2. Antiviral Effect of NUCs
Table 1 summarizes the efficacy of NUCs treatment in a 
48-week large randomized controlled trial with HBeAg-
positive and -negative patients.
2.2.1. Lamivudine (LAM)
In large registration trials, both on HBeAg-positive and 
-negative patients with CHB and those with previous IFN 
failure, a daily dose of 100 mg of LAM was compared to 
0.5 mg of ETV. LAM treatment for 48 weeks resulted in 
suppression of HBV DNA by an average of 5.4 log10 copies/
mL in HBeAg-positive patients and 4.5 log10 copies/mL in 
HBeAg-negative patients. HBeAg seroconversion occurred 
in 18% of patients, rendered HBV DNA undetectable 
(<102 copies/mL) in 36% (HBeAg-positive) to 72% (HBeAg-
negative) of patients (3, 4).
2.2.2. Adefovir (ADV)
In 48-week registration trials, CHB patients who were 
HBeAg-positive and -negative received 10 mg/day of 
ADV. ADV suppressed HBV DNA by 3.5 log10 copies/mL in 
HBeAg-positive patients and 3.9 log10 copies/mL in HBeAg-
negative; HBV DNA decreased to an undetectable level (< 
102 copies/mL) in only 21% of HBeAg-positive patients and 
to 51% of HBeAg-negative patients; suppression of HBV 
DNA was relatively slow; it was also less likely to induce 
HBeAg seroconversion (12%) (5, 6).
2.2.3. Entecavir (ETV)
A daily dose of 0.5 mg of ETV was found to be superior 
to 100 mg of LAM in terms of suppression of HBV DNA 
by 6.9 log10 copies/mL in HBeAg-positive patients and 
by 5.0 log10 copies/mL in HBeAg-negative patients. Hepat Mon. 2011;11(8):601-611
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Therapy with ETV was more likely to decrease HBV DNA 
to undetectable levels (< 102 log10 copies/mL) than LAM 
in 67% of HBeAg-positive patients and in 90% of HBeAg-
negative of patients. Histological improvement was 
achieved in 72% of ETV-treated patients compared to 62% 
in LAM-treated patients (HBeAg positive); and in 70% 
of ETV-treated vs. 61% of LAM-treated patients (HBeAg-
negative). The two drugs, however, did not differ in rates 
of HBeAg seroconversion—21% vs. 18%. Treatment effects 
were maintained with long-term ETV therapy, with HBeAg 
seroconversion rates increasing progressively to 31% at 
year two and 39% at year three. In addition, at the end of 
year two, HBsAg loss was recorded in 5% of ETV-treated 
and 2% of LAM-treated patients (9, 10). In the study of 96 
weeks of treatment with o.5 mg of ETV in naïve Japanese 
patients, resistance was reported in only 1.7% (11).
2.2.4. Telbivudine (TBV)
TBV is a potent L-nucleoside that is believed to cause 
chain termination and is highly potent against HBV in 
cell culture. TBV (600 mg/day) was superior to LAM (100 
mg/day) in suppressing HBV DNA to undetectable levels 
of < 102 copies/mL (60% vs. 40%; a reduction from 6.4 log10 
to 5.5 log10 copies/mL), and in achieving histological 
improvement (65% vs. 56%) but not in normalization 
of ALT (77% vs. 75%) or serological responses (HBeAg 
seroconversion in 23% vs. 22%). In HBeAg-negative 
patients, TBV (600 mg/day) was superior to LAM (100 
mg/day) in suppressing HBV DNA to undetectable levels 
(88% vs. 71%; reduction from 5.2 log10 to 4.4 log10 copies/
mL) but not in achieving histological (67% vs. 66%) or 
normalization of ALT (74% vs. 79%) (7). These responses 
were well maintained during the second year of therapy, 
and HBeAg seroconversion increased to 30% by the end 
of year two (12).
2.2.5. Tenofovir (TDF)
In two 48-week randomized controlled trials, oral 
TDF (300 mg/day) was compared to ADV (10 mg/day) 
in treatment-naive patients with HBeAg-positive and 
-negative CHB. In HBeAg-positive patients, TDF reduced 
HBV DNA levels by 4.5 log10 IU/mL (12 weeks results) and 
suppressed HBV DNA to undetectable levels (< 102 IU/mL) 
in 76% of patients vs. in only 13% in the ADV group. TDF and 
ADV treatments resulted in similar rates of histological 
benefit (74% vs. 68%) and HBeAg seroconversion (21% 
vs. 18%). An important finding was HBsAg loss in 3% of 
patients during the first 48 weeks of therapy in the TDF 
group (8). In the HBeAg-positive group, at the end of year 
two of continuous TDF treatment, HBeAg seroconversion 
increased to 27% and HBsAg loss increased to 6% (13). In 
HBeAg-negative patients, TDF reduced HBV DNA levels 
by 3.0 log10 IU/mL (12 weeks results) and suppressed 
HBV DNA to undetectable levels (< 102 IU/mL) in 93% of 
patients vs. in only 63% in the ADV group. 
2.3. Antiviral Resistance to NUCs
Frequencies of antiviral resistance within five years 
of administration for the five NUCs are shown in Table 
2. Although LAM has the most extensive safety record, 
its current use is limited by the high frequency of LAM 
resistance (24% in year one, and 70% in year four) (14), 
and the availability of more potent agents with superior 
efficacy and markedly improved resistance profiles.
ADV is more expensive than TDF, is less effective, and 
produces higher rates of resistance. Although resistance 
to ADV is slow to emerge, resistant variants increase 
progressively after the first year, reaching 29% in year 
five (16). The advantages of ADV are its limited resistance 
during first two years, the absence of cross-resistance 
with LAM and other L-nucleosides and, therefore, its value 
as treatment for LAM-resistant CHB (17, 18) and for hepatic 
decompensation associated with LAM resistance prior 
to and after liver transplantation (19). The high potency 
and excellent safety profile of ETV are complemented 
by its very high barrier to resistance in treatment-naive 
patients (< 1%) in year four. ETV and TDF are potent HBV 
inhibitors and they have a high barrier to resistance (3, 
20, 21). Therefore, they can be confidently used as the 
Treatment Group  Treatment Duration, y Antiviral-resistance, %
LAM a (14) 1
2
3
4
24
42
53
70
ADV a (naive patients) (6) 1
2
3
4
5
0
3
11
18
29
ETV a (naive patients) (10) 4 < 1
TBV a (naive patients) (7, 12) 1
2
2-5
11-25
TDF a (15) 2 0
Table 2. Frequency of Antiviral Resistance to Nucleoside Analogs Treatment
a Abbreviations: LAM, Lamivudine; ADV, Adefovir; ETV, Entecavir; TVB, Telbivudine; TDF, TenofovirHepat Mon. 2011;11(8):601-611
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first-line monotherapies. The role of monotherapy with 
ETV or TDF could be modified if higher rates of resistance 
become apparent with longer treatment duration. In a 
study of 96 weeks of treatment with TDF, no evidence of 
TDF resistance was found (15).
TBV is a potent inhibitor of HBV but, due to a low genetic 
barrier to resistance, a high incidence of resistance has 
been observed in patients with high baseline levels of 
replication and in those with detectable HBV DNA after 
24 weeks of therapy. In a large registration trial, TBV 
was compared to LAM in HBeAg-positive and -negative 
patients. The frequency of antiviral resistance to TBV 
at one year was 5% of HBeAg-positive and in only 2% of 
HBeAg-negative patients (7).
Virological breakthrough in compliant patients is 
related to viral resistance. Resistance is associated 
with prior treatment with NUCs (i.e., LAM, ADV, TBV, 
emtricitabine) or, in treatment-naive patients, with high 
baseline HBV DNA levels, a slow decline in HBV DNA and 
partial virological response during treatment. Resistance 
should be identified as early as possible before clinical 
breakthrough (i.e. increased ALT) by means of HBV 
DNA monitoring; if possible, the pattern of resistance 
mutations should be identified to adapt therapeutic 
strategies. Indeed, clinical and virological studies 
have demonstrated the benefit of an early treatment 
adaptation—as soon as viral load increases (22, 23). In 
case of resistance, an appropriate rescue therapy should 
be initiated with the most effective antiviral effect and 
the minimal risk to induce multiple drug-resistant 
strains. Therefore, adding-on a second drug without 
cross-resistance is the only efficient strategy.
• LAM resistance: Add TDF (add ADV if TDF is not yet 
available).
•  ADV  resistance:  It  is  recommended  to  switch  to 
TDF if available and add a second drug without cross-
resistance. If an N236T substitution is present, add LAM, 
ETV or TBV or switch to TDF plus emtricitabine. If an 
A181T/V substitution is present, add ETV (the safety of the 
TDF-ETV combination is unknown) or switch to TDF plus 
emtricitabine.
• TBV resistance: Add TDF (add ADV if TDF is not yet 
available). The long-term safety of these combinations is 
unknown.
• ETV resistance: Add TDF (the safety of this combination 
is unknown).
•  TDF  resistance:  Resistance  to  TDF  has  not  been 
described so far. It is recommended that genotyping 
and phenotyping be done by an expert laboratory to 
determine the cross-resistance profile. ETV, TBV, LAM 
or emtricitabine could be added (the safety of these 
combinations is unknown).
2.4. Long-term Therapy with NUCs
HBV DNA levels should be monitored at week 12 to 
ascertain virological response and then every 12 to 24 
weeks. HBV DNA reduction to undetectable levels by real-
time PCR (i.e. < 10–15 IU/mL) should ideally be achieved 
to avoid resistance. HBV DNA monitoring is thus crucial 
to detect treatment failure. In HBeAg-positive patients, 
HBeAg and subsequently anti-HBe antibodies once HBeAg 
is negative should be measured at intervals of 6 to 12 
months. NUCs are cleared by the kidneys, and appropriate 
dose adjustments are recommended for patients with 
reduced creatinine clearance. Drug concentrations 
are comparable in patients with varying degrees of 
hepatic impairment but this has not been fully studied. 
Exacerbations of hepatitis B may occur and require more 
intensive monitoring (monthly in the first three months) 
in patients with cirrhosis. The onset of complications 
in these patients requires urgent management. Renal 
impairment has rarely been reported in patients with 
HIV infection receiving anti-HBV drugs, or in patients 
receiving nephrotoxic drugs and treated with TDF or 
ADV, thus, appropriate monitoring for nephrotoxicity 
and dose adjustments are necessary.
Long-term monitoring for carcinogenesis with ETV 
is ongoing. Myopathy has rarely been reported in CHB 
patients treated with TBV. Peripheral neuropathy has 
been observed in patients treated with PEG IFN and TBV 
and thus this combination should be avoided.
2.5. Treatment with PEG IFN-α
The main theoretical advantages of IFN-α (conventional 
or PEG) are the absence of resistance and the potential 
for immune-mediated containment of HBV infection 
with an opportunity to obtain a sustained virological 
response off-treatment and a chance of HBsAg loss in 
patients who achieve and maintain undetectable HBV 
DNA. Frequent side effects and subcutaneous injection 
are the main disadvantages of IFN-α treatment. IFN-α is 
contraindicated in patients with decompensated HBV-
related cirrhosis or autoimmune disease and in those 
with uncontrolled severe depression or psychosis. Full 
information about the advantages, adverse events and 
inconveniences of PEG IFN-α vs. NUCs should be provided 
so the patient can participate in the decision. There has 
been a resurgence of interest in IFN therapy the past 
five years, largely based on results of large clinical trials 
demonstrating that PEG IFN has more potent antiviral 
activity than standard IFN-α and that in contrast to 
NUCs, it does not result in any antiviral resistance and 
can be given for a finite period rather than indefinitely. 
Therefore, when compared to the standard IFN α-2a in 
a dose of 4.5 million units three times weekly, PEG IFN 
in a dose of 180 μg once weekly for 12 months resulted 
in a greater decline in HBV DNA levels and a higher 
rate of HBeAg seroconversion (33% vs. 25%) (24). Three 
large multicenter trials of PEG IFN therapy have been 
published—two in HBeAg-positive (25, 26) and one in 
HBeAg-negative CHB patients (27). Each study included 
treatment arms in which PEG IFN was used alone or in 
combination with LAM. Two studies used PEG IFN α-2a 
and one used PEG IFN α-2b. The results 24 weeks after Hepat Mon. 2011;11(8):601-611
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treatment are shown in Table 3. 
In a multinational European study, PEG IFN α-2b was 
given in a dose of 100 μg weekly for 32 weeks followed 
by 50 μg weekly until completion of 52 weeks of 
treatment with or without LAM (100 mg daily) in 266 
patients who were HBeAg-positive (25). Seroconversion 
of HBeAg by six months  after treatment occurred in 
similar proportions of patients receiving monotherapy 
as combination therapy (29% vs.  29%) as did loss of 
HBsAg (7% vs. 7%). Suppression of HBV DNA levels and 
HBeAg Status Treatment Arms No. HBV DNA 
Suppression, %
HBV DNA 
Undetectable, 
%
ALT 
Normalization, 
%
HBeAg 
Seroconversion, 
%
Positive (25) PEG IFN 100 μg/wk × 32 
wk→ 50 μg × 20 wk
136 27 7 32 29
PEG IFN 100 μg/wk × 
32 wk→ 50 μg × 20 wk 
+ LAM
130 32 9 35 29
Positive (26) PEG IFN 180 μg/wk × 
48 wk
271 32 14 41 32
PEG IFN 180 μg/wk + 
LAM 48 wk
271 34 14 39 27
LAM for 48 wk 272 22 5 28 19
Negative (27) PEG IFN 180 μg/wk × 
48 wk
177 43 19 59 ―
PEG IFN 180 μg/wk + 
LAM 48 wk
179 44 20 60 ―
LAM for 48 wk 181 29 7 44 ―
Table 3. Summary of Combination Therapy of PEG INF and LAM in CHB Patients 24 Weeks Post-treatment
loss of HBeAg were greater on combination therapy 
than monotherapy, but relapse rates were higher in the 
group that received LAM so that sustained responses 
six months after stopping treatment were equivalent. 
A comparison group receiving LAM alone was not 
included. In a second larger multicenter trial, a total of 
814 patients with HBeAg-positive CHB were given either 
PEG IFN α-2a alone (180 μg once weekly), LAM alone (100 
mg daily), or the combination for 48 weeks (26). Again, 
HBV DNA suppression was greater in patients receiving 
combination therapy than in those receiving either 
PEG IFN or LAM monotherapy. However, rates of HBeAg 
seroconversion six months after discontinuation of 
therapy was greater with PEG IFN than LAM monotherapy 
(32% vs. 19%) and was no higher with combination therapy 
(27%). Loss of HBsAg occurred in 16 of 542 (3%) patients 
who received PEG IFN (alone or with LAM) but in none of 
272 patients receiving LAM alone (P = 0.004).
Finally, in another large multicenter trial, patients 
with HBeAg-negative hepatitis B were treated with PEG 
IFN α-2a alone (180 μg once weekly), LAM alone (100 mg 
daily), or the combination for 48 weeks (27). Six months 
after stopping therapy, the percentage of patients with 
normal ALT values or HBV  DNA levels below 20,000 
copies/mL was significantly higher with PEG IFN 
monotherapy (59% and 43%, respectively) than with 48 
weeks of LAM monotherapy (44% and 29%, respectively). 
Again, the addition of LAM to PEG IFN did not appear 
to increase the response rates even though there was 
greater HBV DNA suppression in combination therapy. 
Furthermore, 3% (12/356) of patients who received PEG 
IFN but none of 181 patients who received LAM alone 
became HBsAg-negative.
These three studies showed that a one-year course of 
PEG IFN induced HBeAg seroconversion in about one-
third of HBeAg-positive patients and induced a lasting 
biochemical and virological response in almost 40% of 
HBeAg-negative patients. Furthermore, therapy with PEG 
IFN led to loss of HBsAg in a small proportion of patients, 
an outcome not seen with a one-year course of LAM 
therapy. Adding LAM to PEG IFN did not increase the rate 
of sustained responses. These results suggested that a 
trial of one-year course of PEG IFN might be appropriate 
in selected patients with CHB, before embarking on long-
term suppressive therapy with NUCs.
3. Section II. Topics of EASL and AASLD 
Presentations at Annual Meetings in 2010
3.1. Efficacy of NUCs
3.1.1. EASL Abstract 1009
Effectiveness of ETV for NUC-naive HBeAg-negative 
CHB patients in clinical practice: A two-year multicenter 
cohort study on 311 patients. Lampertico P.Hepat Mon. 2011;11(8):601-611
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3.1.1.1. Key Results
311 consecutive NUC-naive HBeAg-negative CHB 
patients, recruited in 17 Italian liver units, were treated 
with ETV 0.5 mg for 23 months (10, 28).
• 294 (94%) patients achieved a virological response 
(97% at week 48).
• Two patients had primary non-response at week 12, 
and three (1%) patients had a virological breakthrough. 
No ETV resistance in two patients and suboptimal 
compliance in one patient.
• Two (0.6%) patients cleared HBsAg, seroconverted to 
anti-HBs and stopped ETV.
• No ETV-related serious adverse events were reported.
•  19  (6%)  patients  had  a  partial  virological  response 
at week 48; 50% with HBV DNA > 1000 IU/mL. TDF + ETV 
inhibited HBV replication in the high viral load partial 
responders.
3.1.1.2. Comments
This cohort supports ongoing evidence that ETV was 
effective in this real life population of primarily HBeAg-
negative patients, of whom almost 50% were with LC.
3.1.2. AASLD PO 391
Maintained long-term suppression of HBV replication 
in NUC-naive patients with CHB treated with ETV 
monotherapy in field practice: The Italian multicenter 
experience. Lampertico P, et al.
•  Virological  responses  increased  over  time  in  both 
HBeAg-positive and -negative patients, with more than 
90% achieving undetectable HBV DNA.
•  HBV  remained  suppressed  over  time  in  the  vast 
majority of patients; only 4% of patients showing a short 
lasting virological blip.
• Serological responses, i.e. HBeAg seroconversion and 
HBsAg loss, increased over time. Five patients stopped 
ETV successfully. And most patients developed a normal 
ALT level.
•  Renal  safety:  Serum  creatinine  increased  in  few 
patients (< 1%)—an event not considered drug-related.
• Patient retention rates were 84%.
3.1.2.1. Comments
This reconfirms ETV monotherapy suppresses HBV 
replication in most NUC-naive patients in real practice 
up to 30 months, independently of serology and safety 
profile was consistent with registration studies.
3.1.3. AASLD PO 369
Effectiveness and safety of TDF in field practice: A 
multicenter European cohort study of 737 patients with 
CHB. Lampertico P, et al.
• Most NUC-naive patients achieved undetectable HBV 
DNA by PCR assay and developed a normal ALT level. Viral 
suppression was however significantly faster in patients 
with lower baseline viremia. 
•  Primary  non-response  at  week  12  and  partial 
virological response at week 48 occurred in 3% and 18% of 
the patients, respectively.
• Eight patients seroconverted to anti-HBe with an 18-
month cumulative probability of 32% and two cleared 
HBsAg.
•  In  NUC-experienced  patients,  HBV  DNA  became 
undetectable in almost 74% of the patients, independently 
of treatment regimen (TDF vs. TDF + LAM).
• No major changes of renal function (glomerular and 
tubular) were observed over 18 months of treatment. 
Dose adjustments, hypophosphatemia and increased 
phosphate wasting occurred more frequently in NUC-
experienced patients. 
3.1.3.1. Conclusions
TDF suppressed HBV replication in most NUC-naive 
and NUC-experienced patients in field practice up to 
18 months. The safety profile was favorable with few 
patients, mainly NUC-experienced, showing some 
degrees of renal dysfunction.
3.1.3.2. Comments
This adds another clinical data of TDF. Data on renal 
toxicity seem not to be consistent. Therefore, we will wait 
and see the accumulation of more data.
3.2. Resistance Data
3.2.1. AASLD PO 1365
No resistance to TDF was detected in following up to 192 
weeks of treatment in patients mono-infected with CHB 
virus. Snow-Lampart A, et al. This evaluated NUC-naive, 176 
HBeAg+ and 250 HBeAg– patients on TDF treatment up 
to four years. No resistance was detected in 348 patients 
at 192 weeks. Some doctors chose to add emtricitabine 
(FTC) 200 mg to TDF for seven patients from the 3rd year 
and five from the 4th year on, if patients were confirmed 
to be viremic at week 72 or beyond. They reported good 
tolerability of TDF.
3.2.1.1. Comments
TDF is shown to be free from resistance in this clinical 
trial setting. It needs to be examined in real practice 
usage. (cf. ETV has been presented to have 1.2% resistance 
rate in five years as shown in 2009 EASL guidelines).
3.3. Safety Evaluation of NUCs
3.3.1. Long-term Data
3.3.1.1. EASL Poster 1016
Low rates of nucleos(t)ide-associated adverse events in 
the long-term experience with ETV. Manns M, et al.Hepat Mon. 2011;11(8):601-611
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Adeverse Events (AEs) Total, No.(%)
Any AEs 900 (86)
Serious AEs 169 (16)
Discontinuations due to AEs 14 (1)
Grade 3-4 AEs 203 (19)
Grade 3-4 AEs considered related to ETV 45 (4)
All deaths 27 (3)
Liver-related deaths 12 (1) 
Non-liver-related deaths 15 (1)
Table 4.  Adverse Event (AE) Results from 901 Studies (Mean of 184 Weeks of 
Treatment) (n=1051)
3.3.1.1.1. Key Results
Long-term safety data from the roll-over study ETV-
901 are reviewed, focusing on adverse events (AEs) with 
a potential nucleos(t)ide association. Median exposure 
to ETV in ETV-901 was 184 weeks (almost 3.5 years) (Table 
4). Of the 1,051 patients in this analysis, 448 (46%) had 
prior ETV exposure in previous studies. Overall, the 
most common AEs (related and unrelated) were upper 
respiratory tract infection (27%), headache (20%) and 
nasopharyngitis (16%). Lactate increase or bicarbonate 
decrease occurred in six (< 1%) patients and no cases 
of lactic acidosis syndrome were reported. Rates of 
serious AEs, discontinuations due to AEs, liver disease 
progression and ALT flares were consistent with previous 
Phase III observations. AEs typically associated with 
NUCs use were reported infrequently by investigators. 
Study ETV-901 demonstrates that ETV is generally a well-
tolerated treatment at a dose of 1.0 mg/day when used to 
treat a diverse population of CHB patients.
3.3.1.1.2. Comments
This roll-over study ETV-901 provides an opportunity 
to assess safety events in a large cohort of diverse CHB 
patients, 1051 patients who received long-term ETV (1.0 
mg/day) therapy in the study over a median of 184 weeks. 
Study ETV-901 demonstrates that ETV is a generally well-
tolerated long-term treatment.
3.3.2. Renal Data
3.3.2.1. EASL Abstract 1007
Risk of renal toxicity with TDF for CHB. Gish R, et al.
3.3.2.1.1. Key Results
84 patients on TDF (either monotherapy or in 
combination with another antiviral drug) were matched 
by age (± 5 years) and gender to 84 ETV monotherapy 
patients.
• TDF was shown to be well tolerated: Serum creatinine 
increases of 0.2 mg/dL were found to be common, 
whereas such an increase was rare for the TDF arm and 
less than ETV group (2%, P = 0.029) probably due to a 
significantly higher rate of dose adjustments.
•  History  of  diabetes,  and  transplant,  significantly 
increased the risk of renal injury in all CHB patients (P = 
0.004, and 0.002, respectively).
3.3.2.1.2. Comments
This is a presentation with the risk of TDF with 
nephrotoxicity. The study, however suffers from some 
limitations including, retrospective analysis of data 
that may cause a selection bias for patients with renal 
problems to be given ETV as TDF was given as monotherapy 
or in combination therapy. Patients on ETV had longer 
duration of disease and comorbidities were not equally 
matched between the study arms. Furthermore, dose of 
TDF were often adjusted.
3.3.2.2. EASL Abstract 1010
OPTIB study: A multicenter prospective open label study 
on TDF for CHB patients with suboptimal response to 
ADV or ADV+LAM treatment. Levrero M, et al.
3.3.2.2.1. Key Results
Adults with HBV monoinfection and HBV DNA > 103 
copies/mL after 48 weeks of ADV with or without LAM 
were enrolled and switched to TDF 300 mg daily with or 
without LAM.
• 91 patients were screened and 85 were enrolled. 13 
(15%) patients were switched from ADV to TDF and 72 
(85%) to TDF + LAM combination.
• The median duration of prior ADV therapy was 29.2 
months.
• At 24 weeks of treatment, median HBV DNA fall from 
baseline was 2.02 log10 IU/mL and 62% had HBV DNA 
levels < 69 IU/mL and 49% HBV DNA levels < 12 IU/mL.
• At 48 weeks, 81% of patients had HBV DNA levels < 69 
IU/mL and 65% had HBV DNA levels < 12 IU/mL.
•  The  proportion  of  patients  reaching  negativity 
through 48 weeks was not correlated with HBeAg status 
or the presence of ADV resistance mutations at the 
baseline.
• No clinically significant side effects related to TDF 
were reported.
3.3.2.2.2. Comments
Despite the concerned nucleotide cross-resistance 
profile, this study showed higher response rates than 
other presented data sets. This study implies that TDF 
can be used to salvage patients exposed to ADV and/or 
ADV + LAM.
3.3.2.3. EASL Abstract 1028
Renal safety and antiviral efficacy of TDF monotherapy 
in nucleos(t)ide analogue refractory patients with Hepat Mon. 2011;11(8):601-611
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hepatitis B virus (HBV) mono-infection. vanBommel F, et 
al.
3.3.2.3.1. Key Results
Data from all HBV monoinfected patients treated 
with TDF monotherapy in 19 European centers were 
retrospectively analyzed. Of 343 patients screened, 195 
were found eligible for retrospective data analyses; 137 
were HBeAg-positive. The mean ± SD HBV DNA level was 
6.9 ± 1.5 (range 4-10) log10 copies/mL.
• After 48 months of TDF therapy a mean decrease of 
estimated glomerular filtration rate (eGFR) of 9% was 
observed.
• During the total observation period, 10 patients had a 
moderate decrease (20%–30%) in eGFR; six patients had a 
severe decrease (> 30%), however eGFR remained within 
normal values in most patients and did not decrease to < 
50 mL/min in patients with initially normal eGFR values.
•  TDF  dosage  did  not  need  to  be  adjusted  due  to 
changes in creatinine.
• A model assessing the influence of age on the eGFR 
rates as determined by the MDRD formula confirmed 
a mild decrease in eGFR driven by increase in serum 
creatinine during the 48 months.
• A comparison of the mean eGFR rates in the TDF group 
and the control group showed no significant differences 
in eGFR decrease.
3.3.2.3.2. Comments
In this ongoing real world, independent cohort study 
evaluating TDF in refractory patients, it was shown that 
TDF is not associated with renal issues, though this study 
has excluded patients with higher risk of renal toxicity 
including, concomitant comorbidities—i.e. those with 
kidney disease, arterial hypertension, and/or diabetes. 
3.3.2.4.  AASLD PO 393
Prevalence of renal alterations indicative of proximal 
tubular damage (PTD) in patients with CHB virus infection 
during long-term therapy with TDF. vanBommel, et al.
3.3.2.4.1. Summary
In total, 24 of 61 (39%) patients showed at least one 
sign of PTD, which would be either renal phosphate loss 
(hypophosphatemia and/or TmPO4/GFR↓), glucosuria or 
increased α1-microglobulin/creatinine ratio.
3.3.2.4.2. Conclusion
This study confirms that long-term treatment with TDF 
does not lead to a significant decrease in eGFR in HBV-
infected patients, regardless of age or risk factors for 
kidney dysfunction. However, signs of PTD were prevalent 
in 39% of patients after mean treatment duration of 
29 months. As there were no samples from baseline 
available, there was no clear association between these 
alterations and the use of antiviral agents. Therefore, 
further follow-up data are needed to determine the role 
of TDF therapy in possible proximal tubular damage. 
More specific markers may help to further determine the 
drug’s influence on renal function.
3.3.3. Bone Study
3.3.3.1. AASLD PO 414
High prevalence of reduced bone mineral density 
in patients with CHB under nucleos(t)ide analogues 
treatment. Vigano M, et al. Single center (Universita 
di Milano), cross-sectional study studied 319 patients 
with CHB receiving NUC over a one-year period. Dual 
X-ray absorptiometry (DEXA) of the lumbar spine (LS) 
and femoral neck (FN) revealed that two thirds of CHB 
patients undergoing NUC treatment had reduced 
bone mineral density (BMD), osteoporosis at either LS 
or FN was present in 19% and osteopenia in 49% of the 
patients. Multivariate analysis showed that female sex, 
older age and nucleotide (ADV and TDF) treatment were 
independently associated with a reduced BMD.
3.3.3.1.1. Comments
It is noteworthy that only nucleotides (ADV and TDF), 
not nucleosides (ETV and LAM), was associated with 
reduced BMD. Clinicians may need periodical screening 
of patients for osteoporosis.
3.3.4. PEG IFN for CHB
3.3.4.1. EASL Abstract 98
Extended (two years) treatment with PEG INF α-2a [40 
kD] improves sustained response rates in genotype D 
patients with HBeAg-negative CHB. Lampertico P, et al.
3.3.4.1.1. Results
PEG IFN α-2a 180 μg/week was evaluated for HBeAg-
negative patients with CHB (n = 128) for its duration (48 vs. 
96 weeks) (Table 5). Virologic response was superior with 
96 weeks and notably HBsAg loss retention was observed 
in 10% of patients one year after the therapy of 96 weeks. 
These edges NUCs in efficacy in this study population, 
but it should be noted that different genotypes would 
respond differently and we need further studies in 
patients with various backgrounds.
3.3.4.1.2. Comments
It is still in the experimental stage but this deserves 
to be examined further, although long-term treatment 
poses cost and safety concerns and may limit the number 
of eligible patients for this therapy.Hepat Mon. 2011;11(8):601-611
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Safety Outcome 48-Week PEG IFN a (n = 51) 96-Week PEG IFN (n = 52)
≥ 1 AE a, % 82 77
≥ 1 serious AE, % 14 6
Need for dose reduction, % 31 19
Study withdrawal, %
Due to AEs
Reasons other than safety
16
8
12
12
Death b, No. 1 0
Table 5. Safety Profiles of Extended PEG IFN Therapy 
a Abbreviations: AE, adverse event; PEG IFN, peginterferon
b Patient died of hepatocellular carcinoma during follow-up
3.4. Efficacy and Safety of NUCs in Decompensated 
Cirrhosis
Decompensated cirrhosis is a serious complication 
of CHB. The five-year survival of patients with 
decompensated cirrhosis (14%) has been reported and is 
lower than that for patients with compensated cirrhosis 
(84%) (2). However, suppression of viral replication 
with antiviral therapy has been shown to result in 
clinical improvement and increased survival (2). There 
are limited data on safety and efficacy of NUC therapy 
in patients with CHB and decompensated cirrhosis. 
Summarized here are recently presented data including 
two randomized clinical trials (28, 29), and a cohort 
study on Korean patients pertaining to the use of ETV. in 
this patient population.
3.4.1. EASL Oral Abstract 7
Treatment of decompensated HBV-cirrhosis: results 
from a two-year randomized trial with telbivudine or 
lamivudine. Gane EJ, et al. (Table 6). This study was to 
evaluate clinical and virological outcomes of TBV vs. 
LAM in 232 patients (mean CTP and MELD score TBV 8.1 
and 14.7; LAM 8.5 and 15.5). At baseline, the median age 
was almost 50 years—65% Asian, almost 73% males, and 
approximately 57% HBeAg-negative. This RCT showed 
that both therapies were safe but with high rates of 
rebounds/virological breakthroughs. There was only a 
limited improvement in MELD score of 0.2 with TBV, and 
1 with LAM.
3.4.1.1. Comments
In this large scale study with long-term follow-up, TBV 
was well tolerated, stabilized liver function and had 
comparable tolerability to LAM. Safety profiles were 
similar between treatment arms, however, both TBV 
and LAM showing almost 30% viral breakthrough. This 
result seems to reinforce the need to use potent antiviral 
treatment with low rates of resistance in this population 
with advanced disease, like ETV or TDF.
3.4.2. EASL Abstract 1011
Risk and predictors of mortality or hepatocellular 
carcinoma among ETV- or ADV-treated CHB patients with 
evidence of hepatic decompensation. Liaw Y, et al.
3.4.2.1. Key Results
This industry-sponsored study examined predictors 
of death and HCC in pooled data from ETV-treated and 
ADV-treated patients. The baseline predictors for death 
and HCC were examined in the 191 patients randomized 
to receiving either 1.0 mg/day ETV or 10 mg/day ADV for 
up to 96 weeks using univariate and multivariate Cox 
proportional hazard models with pooled data. Significant 
predictors of mortality in univariate analysis included 
serum creatinine level, MELD score, total bilirubin and 
albumin level. The multivariate analyses showed that 
a decreased hepatic function (increased bilirubin and 
decreased albumin level) is a significant predictor of 
mortality among CHB patients with decompensated liver 
disease treated with nucleos(t)ide analogues. Cumulative 
HCC rates were 12% and 20% among ETV-treated and ADV-
treated patients, respectively. Cumulative death rates 
were 23% and 33% among ETV-treated and ADV-treated 
patients, respectively. HBV genotype B/C was the only 
predictor for development of HCC (Table 7).
3.4.2.2 Comments
The ETV-048 subanalysis reinforces the importance of 
2-Year Outcome (ITT Population) TBV a (n = 114) LAM a (n = 114) P value
HBV DNA, % (< 300 copies/mL) 49 40 0.15
Viral breakthrough, % (HBV DNA > 1 log10 copies/mL above nadir) 28 37 0.16
Composite endpoint, % 34 24 0.004
CTP score improved or stabilized, % 75 74 NS a
Table 6. Outcomes in telbivudine (TBV) and lamivudine (LAM) Groups
a Abbreviations: LAM, lamivudine; NS, not significant; TBV, telbivudinHepat Mon. 2011;11(8):601-611
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One-year Results Compensated (n = 144) Decompensated (n = 55) P value
Change in HBV DNA, (log10 copies/mL)  6.74 ± 1.88  6.82 ± 1.32 0.793
HBV DNA undetectable, No. (%), (< 300 copies/mL by PCR) 113/144 (78.5) 49/55 (89.1) 0.104
HBeAg seroconversion, No. (%) 22/90 (24.4) 6/27 (22.2) 0.812
HBeAg loss, No. (%) 37/90 (41.1) 13/27 (48.1) 0.517
ALT normalization, No. (%) 108/144 (75.0) 42/55 (76.4) 0.535
Table 8. One-year Results of Virologic and Biochemical Indices
biologic risk factors (including baseline characteristics 
and inclusion criteria) as predictors associated with 
increased HCC and/or mortality in decompensated 
cirrhotic patients.
3.5. Cohort Study in Korean Patients
Shim JH et al. Efficacy of ETV in treatment-naive patients 
with HBV-related decompensated cirrhosis (30). This 
cohort study evaluated the effect of ETV monotherapy 
(0.5 mg QD for ≥ 12 months) on viral suppression and 
hepatic function in 70 consecutive treatment-naive 
patients with HBV-associated decompensated cirrhosis 
(defined as CTP ≥ 7 [class B and C]), or the presence of 
portal hypertension complications). Comparator group 
consists of compensated LC patients with HBV (n = 144). 
Virologic response in this decompensated group (n = 55) 
was also compared to compensated cirrhosis. 15 patients 
in the decompensated group received ETV < 12 months 
and therefore were not included in the comparative 
analysis with the compensated group. The baseline 
characteristics for decompensated and compensated 
groups were similar for gender ratio, HBV DNA levels 
(mean ± SD for total patients was 7.34 ± 1.43 log10 copies/
mL; n = 199), and proportion HBeAg-positive (mean for 
total patients: 58.8%; n = 199).
However, in comparison to the compensated group, 
those with hepatic decompensation had a greater mean 
age (52.6 vs. 46.8 year, P < 0.001), lower mean ± SD serum 
ALT (101.9 ± 110.7 vs. 156.5 ± 160.5 IU/L, P = 0.021); and higher 
mean ± SD CTP (8.1 ± 1.7 vs. 5.3 ± 0.05) and MELD (11.5 ± 3.9 
vs. 7.0 ± 1.5) scores (P < 0.001 for both).
Virologic, serologic and biochemical responses after 
12 months of ETV therapy in the decompensated and 
compensated groups are presented in Table 8. Overall, 
at 12 months the rates for undetectable HBV DNA, HBeAg 
loss/seroconversion, and ALT normalization were not 
significantly different between the compensated and 
decompensated groups. In an intention-to-treat analysis 
of efficacy of all 70 patients with decompensated cirrhosis, 
the cumulative rates of HBV DNA undetectability and 
HBeAg loss at 12 months were 92.3% and 54.0%, respectively. 
For those patients with decompensated cirrhosis (n = 
70), the cumulative incidence of HCC was 6.9% at month 
24; four patients developed HCC during the follow-up. 
The cumulative incidence of mortality or OLT was 12.9% 
at month 12 and 17.0% at month 24. For 55 patients with 
decompensated liver function treated with ETV for ≥ 12 
months, improvements from baseline in CTP score and 
its components (albumin, total bilirubin, prothrombin 
time) and MELD score were observed (P < 0.05 for all). 
CTP class A (score 5 or 6) was achieved in 65.5% (30) of the 
patients, and improvement in CTP (≥ 2 points reduction) 
was observed in 49% (27) of the patients after 12 months 
of treatment.
                              Week 48
ETV a ADV a
Cumulative efficacy of NUCs
HBV DNA change from baseline, (log10 copies/mL)
HBV DNA, No. (%) (< 300 copies/mL)
HBeAg loss, No.%
HBeAg seroconversion, No.%
HBsAg loss, No.%
CTP score improvement or no worsening, No.%
CTP score, No.% ( ≥ 2-point reduction)
MELD score change from baseline, Mean (SE) a
 4.66
57 (100)
11 (54)
6 (54)
5 (100)
61 (100)
35 (100)
 2.6 (0.62)
 3.90
20 (91)
18 (51)
10 (51)
0 (91)
67 (91)
27 (91)
 1.7 (0.50)
Cumulative safety of NUCs
Any AE, No.%
Grade 3-4 AEs, No.%
Deaths, No.%
Serum Cr, No.%, (≥ 0.5 mg/dL increase)
HCC, No.%
Discontinuation due to AEs, No.%
91 (89)
55 (54)
23 (23)
17 (17)
12 (12)
7 (7)
86 (97)
42 (47)
29 (33)
21 (24)
18 (20)
5 (6)
Table 7. Cumulative Efficacy and Safety in Both entecavir (ETV) and adefovir dipivoxil (ADV) Groups
a Abbreviations: ADV, adefovir dipivoxil; ETV, entecavir; SE, standard errorHepat Mon. 2011;11(8):601-611
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3.5.1. Comments
This cohort study supports the use of ETV as a first-
line treatment option for NUC-naive patients with 
decompensated HBV cirrhosis. Further follow-up of 
similar studies are needed to identify the optimal 
treatment for these patients and those with LAM-resistant 
HBV cirrhosis. 
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